BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-81. [PMID: 23729361 DOI: 10.1158/1078-0432.CCR-13-0318] [Cited by in Crossref: 382] [Cited by in F6Publishing: 434] [Article Influence: 38.2] [Reference Citation Analysis]
Number Citing Articles
1 Ye R, Yu Y, Zhao R, Han Y, Lu S. Comprehensive molecular characterizations of stage I–III lung adenocarcinoma with tumor spread through air spaces. Front Genet 2023;14. [DOI: 10.3389/fgene.2023.1101443] [Reference Citation Analysis]
2 Lin HM, Wu Y, Yin Y, Niu H, Curran EA, Lovly CM, Humphries MJ. Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States. Clin Lung Cancer 2023;24:e39-49. [PMID: 36376172 DOI: 10.1016/j.cllc.2022.09.010] [Reference Citation Analysis]
3 Guan M, Xu J, Shi Q. Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study. Cancer Genet 2023;270-271:32-8. [PMID: 36502690 DOI: 10.1016/j.cancergen.2022.11.005] [Reference Citation Analysis]
4 Hanley MJ, D'Arcangelo M, Felip E, Garrido P, Zhu J, Ye M, Vranceanu F, Gupta N. A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors. J Clin Pharmacol 2022. [PMID: 36579743 DOI: 10.1002/jcph.2198] [Reference Citation Analysis]
5 Liam CK, Yew CY, Pang YK, Wong CK, Poh ME, Tan JL, Soo CI, Loh TC, Chin KK, Munusamy V, Ibrahim NH. Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers.. [DOI: 10.21203/rs.3.rs-2290231/v1] [Reference Citation Analysis]
6 Bungaro M, Novello S, Passiglia F. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. Curr Treat Options Oncol 2022;23:1699-720. [PMID: 36394791 DOI: 10.1007/s11864-022-01033-4] [Reference Citation Analysis]
7 Li W, Yao H, Gu C, Ren Y, Liu J, An B, Hu W, Li X, Chan AS. Discovery of a potent EGFR and ALK dual mutation inhibitor containing N-(3-((4-((2-(cyclopropylsulfinyl)phenyl)amino)pyrimidin-2-yl)amino) phenyl)acrylamide scaffold. Bioorganic Chemistry 2022;129:106188. [DOI: 10.1016/j.bioorg.2022.106188] [Reference Citation Analysis]
8 Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. Clin Lung Cancer 2022;23:720-30. [PMID: 36038416 DOI: 10.1016/j.cllc.2022.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
10 Xing P, Zhao Q, Zhang L, Wang H, Huang D, Hu P, Sun Y, Shi Y. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. BMC Med 2022;20:453. [PMID: 36424628 DOI: 10.1186/s12916-022-02646-0] [Reference Citation Analysis]
11 Tsui DCC, Drusbosky LM, Wienke S, Gao D, Bubie A, Barbacioru C, Camidge DR. Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung Cancer. Clin Lung Cancer 2022;23:630-8. [PMID: 35961935 DOI: 10.1016/j.cllc.2022.07.002] [Reference Citation Analysis]
12 Ravasio R, Cranmer H, Kearns I, Viti R, Corinti S. Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor. abtpn 2022;9:92-104. [DOI: 10.33393/ao.2022.2450] [Reference Citation Analysis]
13 Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol 2022;15:143. [PMID: 36209184 DOI: 10.1186/s13045-022-01362-9] [Reference Citation Analysis]
14 Shi H, Seegobin K, Heng F, Zhou K, Chen R, Qin H, Manochakian R, Zhao Y, Lou Y. Genomic landscape of lung adenocarcinomas in different races. Front Oncol 2022;12:946625. [DOI: 10.3389/fonc.2022.946625] [Reference Citation Analysis]
15 Wu Y, Ren K, Wan Y, Lin HM. Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors. J Oncol Pharm Pract 2022;:10781552221126174. [PMID: 36131505 DOI: 10.1177/10781552221126174] [Reference Citation Analysis]
16 Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MDC, Deese AR, Zhang L. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers 2022;14:4562. [DOI: 10.3390/cancers14194562] [Reference Citation Analysis]
17 Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J, Yang L, Zhou N, Zu L, Xu X, Song Z, Xu S. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Front Immunol 2022;13:974581. [DOI: 10.3389/fimmu.2022.974581] [Reference Citation Analysis]
18 Gettinger SN, Huber RM, Kim D, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim S, Ahn M, Kim ES, Groen HJ, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clinical and Research Reports 2022;3:100385. [DOI: 10.1016/j.jtocrr.2022.100385] [Reference Citation Analysis]
19 Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Kay S, Walton LJ, Shen J, Popat S, Camidge DR. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. Curr Med Res Opin 2022;38:1587-93. [PMID: 35815801 DOI: 10.1080/03007995.2022.2100653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chen W, Li L, Cheng S, Yu J, Yang Y. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. Disease Markers 2022;2022:1-11. [DOI: 10.1155/2022/2631852] [Reference Citation Analysis]
21 Zhao YP, Long Y. Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy. Curr Med Res Opin 2022;:1-10. [PMID: 35656938 DOI: 10.1080/03007995.2022.2085964] [Reference Citation Analysis]
22 Spinelli M, Du Parcq P, Gupta N, Khorashad J, Viola P. Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung: a possible indicator of poor prognosis. Pathologica 2022;114:221-7. [PMID: 35775708 DOI: 10.32074/1591-951X-334] [Reference Citation Analysis]
23 Maraqa B, Al-Ashhab M, Sughayer MA. Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan. J Int Med Res 2022;50:3000605221104181. [PMID: 35689392 DOI: 10.1177/03000605221104181] [Reference Citation Analysis]
24 Smith JC, Sheltzer JM. Genome-wide identification and analysis of prognostic features in human cancers. Cell Rep 2022;38:110569. [PMID: 35354049 DOI: 10.1016/j.celrep.2022.110569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
25 Désage AL, Léonce C, Swalduz A, Ortiz-Cuaran S. Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. Front Oncol 2022;12:796832. [PMID: 35251972 DOI: 10.3389/fonc.2022.796832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
26 Wang H, Chen Y, Li W, Han Y, Li Q, Ye Z. Pretreatment Thoracic CT Radiomic Features to Predict Brain Metastases in Patients With ALK-Rearranged Non-Small Cell Lung Cancer. Front Genet 2022;13:772090. [DOI: 10.3389/fgene.2022.772090] [Reference Citation Analysis]
27 Zeng J, Gensheimer MF, Rubin DL, Athey S, Shachter RD. Uncovering interpretable potential confounders in electronic medical records. Nat Commun 2022;13:1014. [PMID: 35197467 DOI: 10.1038/s41467-022-28546-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Jang YJ, Kim SY, Jung HK, Kim HR, Kim CH, Lee HR, Kang HJ, Yang SH, Seol H, Na II. Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors. Transl Cancer Res 2021;10:5204-11. [PMID: 35116370 DOI: 10.21037/tcr-21-1235] [Reference Citation Analysis]
29 Zhai X, Wu Q, Pu D, Yin L, Wang W, Zhu D, Xu F. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy. Front Oncol 2021;11:782682. [PMID: 35070986 DOI: 10.3389/fonc.2021.782682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Tu Y, Mei F. miR-3648 promotes lung adenocarcinoma-genesis by inhibiting SOCS2 (suppressor of cytokine signaling 2). Bioengineered 2022;13:3044-56. [DOI: 10.1080/21655979.2021.2017577] [Reference Citation Analysis]
31 Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2021;2:692-729. [PMID: 34977873 DOI: 10.1002/mco2.105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
32 Behel V, Noronha V, Patil V, Menon N, Chandrani P, Kumar R, Rastogi S, Mahajan A, Chougule A, Dutt A, Prabhash K. Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations. Cancer Res Stat Treat 2022;5:312. [DOI: 10.4103/crst.crst_114_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wadhwa R, Paudel KR, Shukla S, Shastri M, Gupta G, Devkota HP, Chellappan DK, Hansbro PM, Dua K. Epigenetic Therapy as a Potential Approach for Targeting Oxidative Stress–Induced Non-Small-Cell Lung Cancer. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects 2022. [DOI: 10.1007/978-981-15-4501-6_106-2] [Reference Citation Analysis]
34 Alite F, Mahadevan A. Radiation Therapy for Metastatic Lung Cancer: Liver Metastasis. Medical Radiology 2022. [DOI: 10.1007/174_2022_330] [Reference Citation Analysis]
35 Ng K, Main K, Forster M. Molecular Targetable Pathways and Therapy—ROS1. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-12-801238-3.11702-7] [Reference Citation Analysis]
36 Wadhwa R, Paudel KR, Shukla S, Shastri M, Gupta G, Devkota HP, Bebawy M, Chellappan DK, Hansbro PM, Dua K. Epigenetic Therapy as a Potential Approach for Targeting Oxidative Stress–Induced Non-small-Cell Lung Cancer. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects 2022. [DOI: 10.1007/978-981-15-9411-3_106] [Reference Citation Analysis]
37 Li W, Zhang J, Wang Z, Li L, Ma J, Zhou X, Wang J, Liang Z, Ying J. Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. Journal of the National Cancer Center 2021;1:123-31. [DOI: 10.1016/j.jncc.2021.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Dezfuli NK, Alipoor SD, Dalil Roofchayee N, Seyfi S, Salimi B, Adcock IM, Mortaz E. Evaluation Expression of miR-146a and miR-155 in Non-Small-Cell Lung Cancer Patients. Front Oncol 2021;11:715677. [PMID: 34790566 DOI: 10.3389/fonc.2021.715677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Inam H, Sokirniy I, Rao Y, Shah A, Naeemikia F, O'Brien E, Dong C, McCandlish DM, Pritchard JR. Genomic and experimental evidence that ALKATI does not predict single agent sensitivity to ALK inhibitors. iScience 2021;24:103343. [PMID: 34825133 DOI: 10.1016/j.isci.2021.103343] [Reference Citation Analysis]
40 Chang F, Zhang H, Chen C, Ke Z, Zhao M, Fan X, Zhang Y. Concomitant genetic alterations are associated with plasma D-dimer level in patients with non-small cell lung cancer. Future Oncol 2021. [PMID: 34789015 DOI: 10.2217/fon-2021-0455] [Reference Citation Analysis]
41 Jang K, Yang J, Lee J, Ko E, Moon H, Yoon M, Jo O, Jeong S, Lee B, Shin K, Hwang W. A Case Report on ROS1-positive Recurrent Non-small-cell Lung Cancer Treated with Crizotinib and Korean Medicine. J Int Korean Med 2021;42:820-832. [DOI: 10.22246/jikm.2021.42.5.820] [Reference Citation Analysis]
42 Yang X, Zhong J, Yu Z, Zhuo M, Zhang M, Chen R, Xia X, Zhao J. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. BMC Cancer 2021;21:1107. [PMID: 34654390 DOI: 10.1186/s12885-021-08824-2] [Reference Citation Analysis]
43 Chen F, Wendl MC, Wyczalkowski MA, Bailey MH, Li Y, Ding L. Moving pan-cancer studies from basic research toward the clinic. Nat Cancer 2021;2:879-90. [PMID: 35121865 DOI: 10.1038/s43018-021-00250-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
44 Baldacci S, Mascaux C, Cortot A. Oncogenèse pulmonaire : mécanismes généraux et addictions oncogéniques. Revue des Maladies Respiratoires Actualités 2021;13:2S12-2S20. [DOI: 10.1016/s1877-1203(21)00091-4] [Reference Citation Analysis]
45 Zhou J, Azizan EAB, Cabrera CP, Fernandes-Rosa FL, Boulkroun S, Argentesi G, Cottrell E, Amar L, Wu X, O'Toole S, Goodchild E, Marker A, Senanayake R, Garg S, Åkerström T, Backman S, Jordan S, Polubothu S, Berney DM, Gluck A, Lines KE, Thakker RV, Tuthill A, Joyce C, Kaski JP, Karet Frankl FE, Metherell LA, Teo AED, Gurnell M, Parvanta L, Drake WM, Wozniak E, Klinzing D, Kuan JL, Tiang Z, Gomez Sanchez CE, Hellman P, Foo RSY, Mein CA, Kinsler VA, Björklund P, Storr HL, Zennaro MC, Brown MJ. Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nat Genet 2021;53:1360-72. [PMID: 34385710 DOI: 10.1038/s41588-021-00906-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
46 Xu Z, Qin F, Yuan L, Wei J, Sun Y, Qin J, Deng K, Zheng T, Li S. EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma. Front Oncol 2021;11:691915. [PMID: 34447695 DOI: 10.3389/fonc.2021.691915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Inoue Y, Matsubara O, Ohira Y, Endo S, Jinn Y. A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib. Respir Med Case Rep 2021;33:101418. [PMID: 34401266 DOI: 10.1016/j.rmcr.2021.101418] [Reference Citation Analysis]
48 Wang Y, Gao Y, Chen HR, Liu H, Fu X, Yan R, You FM, Li ZH. Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report. Clin Med Insights Oncol 2021;15:11795549211028571. [PMID: 34290540 DOI: 10.1177/11795549211028571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Okudela K, Matsumura M, Arai H, Woo T. The nonsmokers' and smokers' pathways in lung adenocarcinoma: Histological progression and molecular bases. Cancer Sci 2021;112:3411-8. [PMID: 34143937 DOI: 10.1111/cas.15031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Ji X, Liu Y, Mei F, Li X, Zhang M, Yao B, Wu R, You J, Pei F. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy. Sci Rep 2021;11:14031. [PMID: 34234236 DOI: 10.1038/s41598-021-93484-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Gu X, Zhang Z, Jiao M, Peng X, Li J, Zhang Q. Discovery of SIPI6473, a New, Potent, and Orally Bioavailable Multikinase Inhibitor for the Treatment of Non-small Cell Lung Cancer. Pharmaceutical Fronts 2021;03:e1-7. [DOI: 10.1055/s-0041-1731081] [Reference Citation Analysis]
52 Zhao Y, Wang S, Yang Z, Dong Y, Wang Y, Zhang L, Hu H, Han B. Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer. Front Oncol 2021;11:665484. [PMID: 34221980 DOI: 10.3389/fonc.2021.665484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Gristina V, La Mantia M, Galvano A, Cutaia S, Barraco N, Castiglia M, Perez A, Bono M, Iacono F, Greco M, Calcara K, Calò V, Rizzo S, Incorvaia L, Lisanti MC, Santanelli G, Sardo D, Inguglia S, Insalaco L, Castellana L, Cusenza S, Pantuso G, Russo A, Bazan V. Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. JMP 2021;2:173-96. [DOI: 10.3390/jmp2020016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
54 Smith JC, Sheltzer JM. Genome-wide identification and analysis of prognostic features in human cancers.. [DOI: 10.1101/2021.06.01.446243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Lu Z, Wang X, Luo Y, Wei J, Zeng Z, Xiong Q, Cai J, Liu A. EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report. Onco Targets Ther 2021;14:2823-8. [PMID: 33935502 DOI: 10.2147/OTT.S294635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Luo W, Jia L, Zhang JW, Wang DJ, Ren Q, Zhang W. Andrographolide Against Lung Cancer-New Pharmacological Insights Based on High-Throughput Metabolomics Analysis Combined with Network Pharmacology. Front Pharmacol 2021;12:596652. [PMID: 33967748 DOI: 10.3389/fphar.2021.596652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Liu Y, Li H, Zhu J, Zhang Y, Liu X, Li R, Zhang Q, Cheng Y. The Prevalence and Concurrent Pathogenic Mutations of KRAS G12C in Northeast Chinese Non-small-cell Lung Cancer Patients. Cancer Manag Res 2021;13:2447-54. [PMID: 33758543 DOI: 10.2147/CMAR.S282617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
58 Heydt C, Wölwer CB, Velazquez Camacho O, Wagener-Ryczek S, Pappesch R, Siemanowski J, Rehker J, Haller F, Agaimy A, Worm K, Herold T, Pfarr N, Weichert W, Kirchner T, Jung A, Kumbrink J, Goering W, Esposito I, Buettner R, Hillmer AM, Merkelbach-Bruse S. Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Med Genomics 2021;14:62. [PMID: 33639937 DOI: 10.1186/s12920-021-00909-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
59 König D, Savic Prince S, Rothschild SI. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel) 2021;13:804. [PMID: 33671873 DOI: 10.3390/cancers13040804] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 18.0] [Reference Citation Analysis]
60 Cipriano É, Magalhães H, Tavares C, Pinto J, Cirnes L, Estevinho F. Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review. Porto Biomed J 2021;6:e124. [PMID: 33884320 DOI: 10.1097/j.pbj.0000000000000124] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Zeng J, Gensheimer MF, Rubin DL, Athey S, Shachter RD. Uncovering interpretable potential confounders in electronic medical records.. [DOI: 10.1101/2021.02.03.21251034] [Reference Citation Analysis]
62 Meng P, Rybczynska AA, Wei J, Terpstra MM, Timens W, Schuuring E, Hiltermann TJN, Groen HJ, van der Wekken AJ, van den Berg A, Kok K. Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients.. [DOI: 10.1101/2021.01.26.21250013] [Reference Citation Analysis]
63 Lee KC, Koh J, Chung DH, Jeon YK. A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma. J Pathol Transl Med 2021;55:139-44. [PMID: 33472332 DOI: 10.4132/jptm.2020.12.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Zhang R, Dong L, Yu J. Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. Front Oncol 2020;10:544579. [PMID: 33520689 DOI: 10.3389/fonc.2020.544579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Novaes LAC, Sussuchi da Silva L, De Marchi P, Cavagna RO, de Paula FE, Zanon MF, Evangelista AF, Albino da Silva EC, Duval da Silva V, Leal LF, Reis RM. Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients. Transl Lung Cancer Res 2021;10:292-303. [PMID: 33569313 DOI: 10.21037/tlcr-20-740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Zhang X, Department of Pathology, The First Affiliated Hospital of University of South China, Hengyang 421001, China, Yu Z, Department of Emergency, The First Affiliated Hospital of University of South China, Hengyang 421001, China. Pathological analysis of hesperetin-derived small cell lung cancer by artificial intelligence technology under fiberoptic bronchoscopy. MBE 2021;18:8538-8558. [DOI: 10.3934/mbe.2021423] [Reference Citation Analysis]
67 Wadhwa R, Paudel KR, Shukla S, Shastri M, Gupta G, Devkota HP, Bebawy M, Chellappan DK, Hansbro PM, Dua K. Epigenetic Therapy as a Potential Approach for Targeting Oxidative Stress–Induced Non-Small-Cell Lung Cancer. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects 2021. [DOI: 10.1007/978-981-15-4501-6_106-1] [Reference Citation Analysis]
68 Kumar M, Kumar K, Singh HP, Nair S, Patel A, Kumar A, Soni S. Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer. South Asian J Cancer 2020;9:109-14. [PMID: 33354554 DOI: 10.1055/s-0040-1721191] [Reference Citation Analysis]
69 Koike C, Okudela K, Matsumura M, Mitsui H, Suzuki T, Arai H, Kataoka T, Ishikawa Y, Umeda S, Tateishi Y, Ohashi K. Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma. Histol Histopathol 2021;36:305-15. [PMID: 33368138 DOI: 10.14670/HH-18-294] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
70 Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C. Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Front Oncol 2020;10:610923. [PMID: 33363040 DOI: 10.3389/fonc.2020.610923] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
71 Cui C, Liu Y, Gerloff D, Rohde C, Pauli C, Köhn M, Misiak D, Oellerich T, Schwartz S, Schmidt LH, Wiewrodt R, Marra A, Hillejan L, Bartel F, Wickenhauser C, Hüttelmaier S, Göllner S, Zhou F, Edemir B, Müller-Tidow C. NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. Oncogene 2021;40:909-21. [PMID: 33288886 DOI: 10.1038/s41388-020-01570-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
72 Dagogo-Jack I, Ritterhouse LL. The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. Transl Lung Cancer Res 2020;9:2557-70. [PMID: 33489818 DOI: 10.21037/tlcr-2019-cnsclc-09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
73 Suda K, Mitsudomi T. Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy. Transl Lung Cancer Res 2020;9:2618-28. [PMID: 33489822 DOI: 10.21037/tlcr-20-186] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
74 Zheng R, Yin Z, Alhatem A, Lyle D, You B, Jiang AS, Liu D, Jobbagy Z, Wang Q, Aisner S, Jiang JG. Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico. Cancers (Basel) 2020;12:E3492. [PMID: 33255238 DOI: 10.3390/cancers12123492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Lin HM, Pan X, Biller A, J Covey K, Huang H, Sugarman R, Scipione F, West H. Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform. Lung Cancer Manag 2020;10:LMT42. [PMID: 33318754 DOI: 10.2217/lmt-2020-0018] [Reference Citation Analysis]
76 Baldacci S, Mascaux C, Cortot A. Oncogenèse pulmonaire : mécanismes généraux et addictions oncogéniques. Revue des Maladies Respiratoires Actualités 2020;12:2S22-2S30. [DOI: 10.1016/s1877-1203(20)30080-x] [Reference Citation Analysis]
77 Hung YP, Chirieac LR. How should molecular findings be integrated in the classification for lung cancer? Transl Lung Cancer Res 2020;9:2245-54. [PMID: 33209647 DOI: 10.21037/tlcr-20-153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Kadlec B. Alectinib in the treatment of advanced ALK + NSCLC. Onkologie 2020;14:135-138. [DOI: 10.36290/xon.2020.073] [Reference Citation Analysis]
79 Sepúlveda-hermosilla G, Blanco A, Freire M, Lizana R, Cáceres-molima J, Ampuero D, Pérez P, Ramos L, Aren O, Chernilo S, Spencer ML, Flores J, Bernal G, Olea MA, Rasse G, Sánchez C, Marcelain K, Rivas S, Amorim MGD, Branco G, Nunes DN, Dias-neto E, Freitas HC, Fernández C, Assar R, Armisén R, NIRVANA Team. Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations.. [DOI: 10.1101/2020.09.11.20171025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Shen HB, Li J, Yao YS, Yang ZH, Zhou YJ, Chen W, Hu TJ. Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort. Cancer Manag Res 2020;12:7427-37. [PMID: 32884354 DOI: 10.2147/CMAR.S254139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol 2020;38:3592-603. [PMID: 32780660 DOI: 10.1200/JCO.20.00505] [Cited by in Crossref: 147] [Cited by in F6Publishing: 155] [Article Influence: 49.0] [Reference Citation Analysis]
82 Walls M, Walls GM, James JA, Crawford KT, Abdulkhalek H, Lynch TB, Peace AJ, McManus TE, Evans OR. Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature. BMC Pulm Med 2020;20:209. [PMID: 32762670 DOI: 10.1186/s12890-020-01249-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
83 Zhang B, Zhang L, Yue D, Li C, Zhang H, Ye J, Gao L, Zhao X, Chen C, Huo Y, Pang C, Li Y, Chen Y, Chuai S, Zhang Z, Giaccone G, Wang C. Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. Transl Lung Cancer Res 2020;9:1187-201. [PMID: 32953497 DOI: 10.21037/tlcr-19-664] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
84 Li D, Ding L, Ran W, Huang Y, Li G, Wang C, Xiao Y, Wang X, Lin D, Xing X. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution. Thorac Cancer 2020;11:2580-9. [PMID: 32729257 DOI: 10.1111/1759-7714.13577] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
85 Paliouras AR, Buzzetti M, Shi L, Donaldson IJ, Magee P, Sahoo S, Leong HS, Fassan M, Carter M, Di Leva G, Krebs MG, Blackhall F, Lovly CM, Garofalo M. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. EMBO Mol Med 2020;12:e11099. [PMID: 32558295 DOI: 10.15252/emmm.201911099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
86 Xu CW, Lei L, Wang WX, Lin L, Zhu YC, Wang H, Miao LY, Wang LP, Zhuang W, Fang MY, Lv TF, Song Y. Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs. Transl Oncol 2020;13:100791. [PMID: 32492620 DOI: 10.1016/j.tranon.2020.100791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
87 Wang S, Qu X, Cao L, Hu X, Hou K, Liu Y, Che X. Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer. Cancer Manag Res 2020;12:4029-38. [PMID: 32581578 DOI: 10.2147/CMAR.S250822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
88 El Yacoubi H, Sow ML, Kettani F, Gamra L, Mestari A, Jabri L, Elghissassi I, Errihani H. Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study. BMC Cancer 2020;20:479. [PMID: 32460789 DOI: 10.1186/s12885-020-06973-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
89 Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol 2020;13:58. [PMID: 32448366 DOI: 10.1186/s13045-020-00881-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 69] [Article Influence: 19.0] [Reference Citation Analysis]
90 Cofano F, Monticelli M, Ajello M, Zenga F, Marengo N, Di Perna G, Altieri R, Cassoni P, Bertero L, Melcarne A, Tartara F, Ducati A, Garbossa D. The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. Cancer Control 2019;26:1073274819870549. [PMID: 31865766 DOI: 10.1177/1073274819870549] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
91 Foggetti G, Li C, Cai H, Hellyer JA, Lin W, Ayeni D, Hastings K, Choi J, Wurtz A, Andrejka L, Maghini D, Rashleigh N, Levy S, Homer R, Gettinger S, Diehn M, Wakelee HA, Petrov DA, Winslow MM, Politi K. Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo.. [DOI: 10.1101/2020.04.13.036921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Madsen AT, Winther-Larsen A, McCulloch T, Meldgaard P, Sorensen BS. Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. Cancers (Basel) 2020;12:E947. [PMID: 32290439 DOI: 10.3390/cancers12040947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
93 Kim JS, Kang EJ. Targeted Therapy for Non-Small Cell Lung Cancer. Korean J Med 2020;95:78-88. [DOI: 10.3904/kjm.2020.95.2.78] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Dang AH, Tran VU, Tran TT, Thi Pham HA, Le DT, Nguyen L, Nguyen NV, Thi Nguyen TH, Nguyen CV, Le HT, Thi Nguyen ML, Le VT, Nguyen PH, Vo BT, Thi Dao HT, Nguyen LT, Van Nguyen TC, Bui QN, Nguyen LH, Nguyen NH, Thi Nguyen QT, Le TX, Do TT, Dinh KT, Do HN, Phan MD, Nguyen HN, Tran LS, Giang H. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Sci Rep 2020;10:2707. [PMID: 32066856 DOI: 10.1038/s41598-020-59744-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
95 Zhang Y, Shen WX, Zhou LN, Tang M, Tan Y, Feng CX, Li P, Wang LQ, Chen MB. The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China. Biomed Res Int 2020;2020:9387167. [PMID: 32047821 DOI: 10.1155/2020/9387167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
96 Zhu C, Zhuang W, Chen L, Yang W, Ou WB. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Transl Lung Cancer Res 2020;9:111-38. [PMID: 32206559 DOI: 10.21037/tlcr.2020.01.09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
97 Lu S, Lu C, Xiao Y, Zhu W, He Q, Xie B, Zhou J, Tao Y, Liu S, Xiao D. Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer. J Cancer 2020;11:1525-31. [PMID: 32047559 DOI: 10.7150/jca.36580] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
98 Zhao Y, Wang S, Zhang B, Qiao R, Xu J, Zhang L, Zhang Y, Han B. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Target Oncol 2019;14:169-78. [PMID: 30888598 DOI: 10.1007/s11523-019-00628-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
99 Vajjha S, Bommuluri V, Rumalla CS, Kaliyaperumal M, Korupolu RB, chopella V. Forced degradation of Ceritinib under stress conditions: Structural interpretation of novel degradants using HR-MS/MS and NMR. Materials Today: Proceedings 2020;33:2067-2076. [DOI: 10.1016/j.matpr.2020.01.588] [Reference Citation Analysis]
100 Tran LS, Pham HT, Tran VU, Tran TT, Dang AH, Le DT, Nguyen SL, Nguyen NV, Nguyen TV, Vo BT, Dao HT, Nguyen NH, Tran TH, Nguyen CV, Pham PC, Dang-Mai AT, Dinh-Nguyen TK, Phan VH, Do TT, Truong Dinh K, Do HN, Phan MD, Giang H, Nguyen HN. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. PLoS One 2019;14:e0226193. [PMID: 31841547 DOI: 10.1371/journal.pone.0226193] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
101 Smolle E, Leithner K, Olschewski H. Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations. Thorac Cancer 2020;11:205-15. [PMID: 31799812 DOI: 10.1111/1759-7714.13246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
102 Mendes C, Serpa J. Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer. Antioxidants (Basel) 2019;8:E603. [PMID: 31795465 DOI: 10.3390/antiox8120603] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
103 Anjali VR, Pandey R, Srivastava A, Rajeshwari M, Pandey D, Sharma MC. Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium. Respir Med Case Rep 2019;28:100954. [PMID: 31720204 DOI: 10.1016/j.rmcr.2019.100954] [Reference Citation Analysis]
104 Xu X, Huang L, Chen J, Wen J, Liu D, Cao J, Wang J, Fan M. Application of radiomics signature captured from pretreatment thoracic CT to predict brain metastases in stage III/IV ALK-positive non-small cell lung cancer patients. J Thorac Dis 2019;11:4516-28. [PMID: 31903240 DOI: 10.21037/jtd.2019.11.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
105 Baldacci S, Mascaux C, Cortot A. Oncogenèse pulmonaire: comprendre les addictions oncogéniques et les résistances. Revue des Maladies Respiratoires Actualités 2019;11:184-192. [DOI: 10.1016/s1877-1203(19)30085-0] [Reference Citation Analysis]
106 Liu Y, Ye X, Yu Y, Lu S. Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma. J Thorac Dis 2019;11:4258-70. [PMID: 31737311 DOI: 10.21037/jtd.2019.09.65] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
107 Bi R, Bai Q, Zhu X, Tu X, Cai X, Jiang W, Xu X, Tang S, Ge H, Chang B, Cheng Y, Gan H, Zhou X, Yang W. ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma. Diagn Pathol 2019;14:96. [PMID: 31455365 DOI: 10.1186/s13000-019-0864-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
108 Kim TH, Woo S, Yoon SH, Halpenny DF, Han S, Suh CH. CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2019;213:1059-72. [PMID: 31414902 DOI: 10.2214/AJR.19.21485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
109 Yu H, Sun S, Hu X, Xia J, Wang J, Chen H. Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. Onco Targets Ther 2019;12:6481-95. [PMID: 31616158 DOI: 10.2147/OTT.S185115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
110 Tang Z, Wang L, Tang G, Medeiros LJ. Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. Int J Mol Sci 2019;20:E3939. [PMID: 31412611 DOI: 10.3390/ijms20163939] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
111 Xing P, Ma D, Wang Q, Hao X, Wang M, Wang Y, Shan L, Xin T, Liang L, Liang H, Du Y, Zhang Z, Li J. Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. Chin J Cancer Res 2019;31:481-8. [PMID: 31354217 DOI: 10.21147/j.issn.1000-9604.2019.03.10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
112 Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers (Basel) 2019;11:E923. [PMID: 31266248 DOI: 10.3390/cancers11070923] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 16.3] [Reference Citation Analysis]
113 Mitra D, Chen YH, Li R, Hermann G, Atkins K, Kozono D, Baldini EH, Aizer A, Chukwueke U, Mak RH. EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clin Transl Radiat Oncol 2019;18:32-8. [PMID: 31341973 DOI: 10.1016/j.ctro.2019.06.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
114 Cai L, Luo D, Yao B, Yang DM, Lin S, Girard L, DeBerardinis RJ, Minna JD, Xie Y, Xiao G. Systematic Analysis of Gene Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma with a Case Study of FAM83A and FAM83B. Cancers (Basel) 2019;11:E886. [PMID: 31242643 DOI: 10.3390/cancers11060886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
115 Dhieb D, Belguith I, Capelli L, Chiadini E, Canale M, Bravaccini S, Yangui I, Boudawara O, Jlidi R, Boudawara T, Calistri D, Keskes LA, Ulivi P. Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma. Cells 2019;8:E514. [PMID: 31141932 DOI: 10.3390/cells8060514] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
116 Chen F, Gu Q, Hu C, Cai X, Lei S. Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion. Onco Targets Ther 2019;12:3321-5. [PMID: 31118683 DOI: 10.2147/OTT.S196751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
117 Zhang C, Leighl NB, Wu YL, Zhong WZ. Emerging therapies for non-small cell lung cancer. J Hematol Oncol 2019;12:45. [PMID: 31023335 DOI: 10.1186/s13045-019-0731-8] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 16.5] [Reference Citation Analysis]
118 Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X, Zhou C. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med 2019;8:2858-66. [PMID: 31016879 DOI: 10.1002/cam4.2183] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
119 Cao Y, Zhu W, Chen W, Wu J, Hou G, Li Y. Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis. Dis Markers 2019;2019:5451290. [PMID: 31093306 DOI: 10.1155/2019/5451290] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
120 Hu Y, Xiao L, Yang N, Zhang Y. Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient. Thorac Cancer 2019;10:1252-5. [PMID: 30788907 DOI: 10.1111/1759-7714.13015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
121 Bansal M, He J, Peyton M, Kustagi M, Iyer A, Comb M, White M, Minna JD, Califano A. Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis. PLoS One 2019;14:e0208646. [PMID: 30615629 DOI: 10.1371/journal.pone.0208646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
122 Wang Y, Li X, Liu X, Chen Y, Yang C, Tan C, Wang B, Sun Y, Zhang X, Gao Y, Ding J, Meng L. Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer. Cancer Biol Med 2019;16:66-83. [PMID: 31119047 DOI: 10.20892/j.issn.2095-3941.2018.0361] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
123 Basu A, Nieva J. KRAS-Mutated Lung Cancer. Targeted Therapies for Lung Cancer 2019. [DOI: 10.1007/978-3-030-17832-1_10] [Reference Citation Analysis]
124 Alidousty C, Baar T, Heydt C, Wagener-Ryczek S, Kron A, Wolf J, Buettner R, Schultheis AM. Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology. J Thorac Dis 2019;11:S3-8. [PMID: 30775023 DOI: 10.21037/jtd.2018.12.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
125 Pal P, Cabanero M, Tsao M. Pulmonary Adenocarcinoma—Pathology and Molecular Testing. Pulmonary Adenocarcinoma: Approaches to Treatment 2019. [DOI: 10.1016/b978-0-323-55433-6.00002-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Lee J, Park CK, Yoon HK, Sa YJ, Woo IS, Kim HR, Kim SY, Kim TJ. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. Thorac Cancer 2019;10:103-10. [PMID: 30475455 DOI: 10.1111/1759-7714.12917] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
127 Yoshida R, Sasaki T, Umekage Y, Tanno S, Ono Y, Ogata M, Chiba S, Mizukami Y, Ohsaki Y. Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR. BMC Cancer 2018;18:1136. [PMID: 30453899 DOI: 10.1186/s12885-018-5031-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
128 Sacher AG. Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to EGFR Mutation Detection in Non–Small-Cell Lung Cancer. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00125] [Reference Citation Analysis]
129 Hung YP, Sholl LM. Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. Adv Anat Pathol 2018;25:374-86. [PMID: 30188361 DOI: 10.1097/PAP.0000000000000206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
130 Wang X, Zhong D. [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:686-91. [PMID: 30201068 DOI: 10.3779/j.issn.1009-3419.2018.09.07] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
131 Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clin Cancer Res 2019;25:346-57. [PMID: 30257981 DOI: 10.1158/1078-0432.CCR-18-1129] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
132 Lee DH, Tsao MS, Kambartel KO, Isobe H, Huang MS, Barrios CH, Khattak A, de Marinis F, Kothari S, Arunachalam A, Cao X, Burke T, Valladares A, de Castro J. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study. PLoS One. 2018;13:e0202865. [PMID: 30148862 DOI: 10.1371/journal.pone.0202865] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
133 Akamine T, Toyokawa G, Tagawa T, Seto T. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. Onco Targets Ther 2018;11:5093-101. [PMID: 30174447 DOI: 10.2147/OTT.S165511] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
134 Zhu YC, Wang WX, Xu CW, Zhuang W, Song ZB, Du KQ, Chen G, Lv TF, Song Y. A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib. Cancer Biol Ther 2018;19:1097-101. [PMID: 30095326 DOI: 10.1080/15384047.2018.1491506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
135 Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight 2018;3:120858. [PMID: 30089719 DOI: 10.1172/jci.insight.120858] [Cited by in Crossref: 80] [Cited by in F6Publishing: 89] [Article Influence: 16.0] [Reference Citation Analysis]
136 Auliac JB, Monnet I, Dubos-Arvis C, Chiappa AM, Baize N, Bota S, Vergnenegre A, Doubre H, Locher C, Bizieux A, Robinet G, Chouaid C. Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study). Target Oncol 2017;12:833-8. [PMID: 28762087 DOI: 10.1007/s11523-017-0520-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
137 Bui KT, Cooper WA, Kao S, Boyer M. Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. J Clin Med 2018;7:E192. [PMID: 30065223 DOI: 10.3390/jcm7080192] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
138 Alidousty C, Baar T, Martelotto LG, Heydt C, Wagener S, Fassunke J, Duerbaum N, Scheel AH, Frank S, Holz B, Binot E, Kron A, Merkelbach-Bruse S, Ihle MA, Wolf J, Buettner R, Schultheis AM. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations. J Pathol 2018;246:67-76. [PMID: 29885057 DOI: 10.1002/path.5110] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
139 Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol 2018;2018. [PMID: 30370396 DOI: 10.1200/PO.17.00299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
140 Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018;2018. [PMID: 30215037 DOI: 10.1200/po.18.00037] [Cited by in Crossref: 55] [Cited by in F6Publishing: 71] [Article Influence: 11.0] [Reference Citation Analysis]
141 Ni W, Chen W, Lu Y. Emerging findings into molecular mechanism of brain metastasis. Cancer Med 2018;7:3820-33. [PMID: 29992751 DOI: 10.1002/cam4.1667] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
142 Moatter S, Anwar N, Moatter T, Pervez S. Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin. Asian Pac J Cancer Prev 2018;19:1735-8. [PMID: 29938474 DOI: 10.22034/APJCP.2018.19.6.1735] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials. Curr Oncol 2018;25:S59-67. [PMID: 29910648 DOI: 10.3747/co.25.3760] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
144 Jakobsen JN, Santoni-Rugiu E, Grauslund M, Melchior L, Sørensen JB. Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment. Oncotarget 2018;9:26195-208. [PMID: 29899852 DOI: 10.18632/oncotarget.25490] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
145 Pedrosa RMSM, Mustafa DAM, Aerts JGJV, Kros JM. Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis. Front Oncol 2018;8:159. [PMID: 29868480 DOI: 10.3389/fonc.2018.00159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
146 Churilla TM, Weiss SE. Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer. Curr Oncol Rep. 2018;20:54. [PMID: 29736685 DOI: 10.1007/s11912-018-0695-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
147 Zhang S, Yan B, Zheng J, Zhao J, Zhou J. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis. Oncotarget 2016;7:63758-66. [PMID: 27563816 DOI: 10.18632/oncotarget.11494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
148 Gkolfinopoulos S, Mountzios G. Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer. Ann Transl Med 2018;6:142. [PMID: 29862231 DOI: 10.21037/atm.2018.04.28] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
149 Bansal M, He J, Peyton M, Kaustagi M, Iyer A, Comb M, White M, Minna J, Califano A. Elucidating synergistic dependencies in lung adenocarcinoma by proteome-wide signaling-network analysis.. [DOI: 10.1101/289603] [Reference Citation Analysis]
150 Lindquist KE, Karlsson A, Levéen P, Brunnström H, Reuterswärd C, Holm K, Jönsson M, Annersten K, Rosengren F, Jirström K, Kosieradzki J, Ek L, Borg Å, Planck M, Jönsson G, Staaf J. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget 2017;8:34796-810. [PMID: 28415793 DOI: 10.18632/oncotarget.16276] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
151 Lee B, Lee T, Lee SH, Choi YL, Han J. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget 2016;7:23874-84. [PMID: 26992209 DOI: 10.18632/oncotarget.8074] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
152 Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, Zhong WZ, Wu YL, Yang JJ. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget 2016;7:65185-95. [PMID: 27533086 DOI: 10.18632/oncotarget.11218] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
153 Román M, Baraibar I, López I, Nadal E, Rolfo C, Vicent S, Gil-Bazo I. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer 2018;17:33. [PMID: 29455666 DOI: 10.1186/s12943-018-0789-x] [Cited by in Crossref: 178] [Cited by in F6Publishing: 186] [Article Influence: 35.6] [Reference Citation Analysis]
154 Cerrato A, Visconti R, Celetti A. The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer. Mol Cancer 2018;17:46. [PMID: 29455670 DOI: 10.1186/s12943-018-0799-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
155 Portier B. Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS). Precision Molecular Pathology of Lung Cancer 2018. [DOI: 10.1007/978-3-319-62941-4_7] [Reference Citation Analysis]
156 Dubey AP, Pathi N, Rathore A, Viswanath S, Pathak A, Sud R, Rai SK. Clinicopathological Profile of Anaplastic Lymphoma Kinase-positive Nonsmall Cell Lung Cancer: An Indian Perspective. Indian Journal of Medical and Paediatric Oncology 2018;39:32-35. [DOI: 10.4103/ijmpo.ijmpo_19_17] [Reference Citation Analysis]
157 Varella-garcia M, Cho BC. Copy Number Abnormalities and Gene Fusions in Lung Cancer. IASLC Thoracic Oncology 2018. [DOI: 10.1016/b978-0-323-52357-8.00010-x] [Reference Citation Analysis]
158 Mahadevan NR, Sholl LM. Translocations as Predictive Biomarkers in Lung Cancer. Precision Molecular Pathology of Lung Cancer 2018. [DOI: 10.1007/978-3-319-62941-4_12] [Reference Citation Analysis]
159 DiBonaventura MD, Wong W, Shah-Manek B, Schulz M. Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. Onco Targets Ther 2018;11:75-82. [PMID: 29317835 DOI: 10.2147/OTT.S144960] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
160 Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget 2018;9:6630-43. [PMID: 29464099 DOI: 10.18632/oncotarget.23553] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
161 Zhu YC, Liao XH, Wang WX, Xu CW, Zhuang W, Wei JG, Du KQ. Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma. Thorac Cancer 2018;9:324-7. [PMID: 29251824 DOI: 10.1111/1759-7714.12578] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
162 Niu X, Chuang JC, Berry GJ, Wakelee HA. Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. Curr Treat Options Oncol 2017;18:71. [PMID: 29143897 DOI: 10.1007/s11864-017-0513-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
163 Jambhekar N. Evolving concepts in lung cancer pathology and its impact on thoracic oncology practice. Indian J Thorac Cardiovasc Surg 2018;34:4-10. [DOI: 10.1007/s12055-017-0609-8] [Reference Citation Analysis]
164 Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016;27 Suppl 3:iii42-50. [PMID: 27573756 DOI: 10.1093/annonc/mdw305] [Cited by in Crossref: 72] [Cited by in F6Publishing: 86] [Article Influence: 12.0] [Reference Citation Analysis]
165 Tuli R, Lo S, Koo J, Pishvaian M, Bender RJ, Petricoin E, Brody J, Nissen N. Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. JCO Precision Oncology 2017. [DOI: 10.1200/po.17.00016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
166 Isobe H, Mori K, Minato K, Katsura H, Taniguchi K, Arunachalam A, Kothari S, Cao X, Kato T. Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan. Lung Cancer (Auckl) 2017;8:191-206. [PMID: 29123433 DOI: 10.2147/LCTT.S140491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
167 Sholl L. Molecular diagnostics of lung cancer in the clinic. Transl Lung Cancer Res 2017;6:560-9. [PMID: 29114472 DOI: 10.21037/tlcr.2017.08.03] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
168 Farago AF, Azzoli CG. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl Lung Cancer Res 2017;6:550-9. [PMID: 29114471 DOI: 10.21037/tlcr.2017.08.02] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
169 Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R. Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget 2017;8:92265-74. [PMID: 29190913 DOI: 10.18632/oncotarget.21182] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
170 Sutton BC, Birse RT, Maggert K, Ray T, Hobbs J, Ezenekwe A, Kazmierczak J, Mosko M, Kish J, Bullock A, Shi Z, Stack MS, Irwin D. Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX® HS, a new highly sensitive assay for the MassARRAY® System. PLoS One 2017;12:e0183715. [PMID: 28926605 DOI: 10.1371/journal.pone.0183715] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
171 Faehling M, Schwenk B, Kramberg S, Eckert R, Volckmar AL, Stenzinger A, Sträter J. Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. Oncotarget 2017;8:77897-914. [PMID: 29100434 DOI: 10.18632/oncotarget.20857] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
172 Muller IB, de Langen AJ, Giovannetti E, Peters GJ. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther 2017;10:4535-41. [PMID: 28979145 DOI: 10.2147/OTT.S109493] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
173 Ma W, Guo L, Shan L, Liu X, Lyu N, Ying J. Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis. Sci Rep 2017;7:10961. [PMID: 28887531 DOI: 10.1038/s41598-017-11453-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
174 Baldacci S, Gervais R, Cortot A. Les cancers bronchiques non à petites cellules EGFR-mutés. Revue des Maladies Respiratoires Actualités 2017;9:213-223. [DOI: 10.1016/s1877-1203(17)30054-x] [Reference Citation Analysis]
175 Lin JJ, Shaw AT. Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol 2017;12:1611-25. [PMID: 28818606 DOI: 10.1016/j.jtho.2017.08.002] [Cited by in Crossref: 138] [Cited by in F6Publishing: 149] [Article Influence: 23.0] [Reference Citation Analysis]
176 Hofman P. ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice. Cancers (Basel) 2017;9:E107. [PMID: 28805682 DOI: 10.3390/cancers9080107] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
177 Li Y, Su S, Cai G, Lin Q, Zhou Y, Ouyang J, Chen B, Ye J, Wu X, Chen C. Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature. Mol Clin Oncol 2017;7:173-82. [PMID: 28781781 DOI: 10.3892/mco.2017.1306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Pailler E, Faugeroux V, Oulhen M, Catelain C, Farace F. Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time? Transl Lung Cancer Res 2017;6:444-53. [PMID: 28904888 DOI: 10.21037/tlcr.2017.07.01] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
179 Schallenberg S, Merkelbach-Bruse S, Buettner R. Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch 2017;471:221-33. [PMID: 28730537 DOI: 10.1007/s00428-017-2183-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
180 Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Des Devel Ther 2017;11:2047-63. [PMID: 28740365 DOI: 10.2147/DDDT.S113500] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
181 Sekine I. What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer? J Thorac Dis 2017;9:E447-50. [PMID: 28616306 DOI: 10.21037/jtd.2017.04.43] [Reference Citation Analysis]
182 Arbour KC, Riely GJ. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017;31:101-11. [PMID: 27912826 DOI: 10.1016/j.hoc.2016.08.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
183 Park EH, Lee HY, Kim JW, Yeo CD. Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocation. J Thorac Dis 2017;9:E543-6. [PMID: 28740693 DOI: 10.21037/jtd.2017.05.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
184 Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F. Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. Cancer Res 2017;77:2222-30. [PMID: 28461563 DOI: 10.1158/0008-5472.CAN-16-3072] [Cited by in Crossref: 44] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
185 Marín A, Renner A, Itriago L, Álvarez M. METÁSTASIS CEREBRALES: UNA MIRADA BIOLÓGICA Y CLÍNICA. Revista Médica Clínica Las Condes 2017;28:437-449. [DOI: 10.1016/j.rmclc.2017.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
186 Yang Y, Qin SK, Zhu J, Wang R, Li YM, Xie ZY, Wu Q. A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing-Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib. Mayo Clin Proc Innov Qual Outcomes 2017;1:111-6. [PMID: 30225407 DOI: 10.1016/j.mayocpiqo.2017.04.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
187 Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget 2017;8:59889-900. [PMID: 28938691 DOI: 10.18632/oncotarget.17431] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
188 Possidente L, Landriscina M, Patitucci G, Borgia L, Lalinga V, Vita G. ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features. Med Oncol 2017;34:76. [PMID: 28364271 DOI: 10.1007/s12032-017-0936-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
189 Cho J, Choi SM, Lee J, Lee CH, Lee SM, Kim DW, Yim JJ, Kim YT, Yoo CG, Kim YW, Han SK, Park YS. Proportion and clinical features of never-smokers with non-small cell lung cancer. Chin J Cancer 2017;36:20. [PMID: 28179026 DOI: 10.1186/s40880-017-0187-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
190 Gevaert O, Echegaray S, Khuong A, Hoang CD, Shrager JB, Jensen KC, Berry GJ, Guo HH, Lau C, Plevritis SK, Rubin DL, Napel S, Leung AN. Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Sci Rep 2017;7:41674. [PMID: 28139704 DOI: 10.1038/srep41674] [Cited by in Crossref: 96] [Cited by in F6Publishing: 103] [Article Influence: 16.0] [Reference Citation Analysis]
191 Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ, Lennerz JK, Shaw AT. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12:872-877. [PMID: 28088512 DOI: 10.1016/j.jtho.2017.01.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
192 Malik PS, Singh N. ASCENDing the anaplastic lymphoma kinase ladder: a tale of two C-nibs. J Thorac Dis 2016;8:E1514-6. [PMID: 28066647 DOI: 10.21037/jtd.2016.11.78] [Reference Citation Analysis]
193 Wang L, Zhang R, Fang B. Patient-Derived Xenografts From Lung Cancer and Their Potential Applications. Patient Derived Tumor Xenograft Models 2017. [DOI: 10.1016/b978-0-12-804010-2.00020-5] [Reference Citation Analysis]
194 Facchinetti F, Proto C, Minari R, Garassino M, Tiseo M. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handb Exp Pharmacol 2018;249:63-89. [PMID: 28332047 DOI: 10.1007/164_2017_16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
195 Hatcher JM, Gray NS. Small Molecule Inhibitors of ALK. Topics in Medicinal Chemistry 2017. [DOI: 10.1007/7355_2017_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
196 Matsumura M, Okudela K, Kojima Y, Umeda S, Tateishi Y, Sekine A, Arai H, Woo T, Tajiri M, Ohashi K. A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element. PLoS One 2016;11:e0166795. [PMID: 27861549 DOI: 10.1371/journal.pone.0166795] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
197 Lee K, Um SW, Jeong BH, Yang JW, Choi YL, Han J, Kim H, Kwon OJ. Triple Gene Analysis Using Samples Obtained by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration. Intern Med 2016;55:3105-11. [PMID: 27803402 DOI: 10.2169/internalmedicine.55.6794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
198 Ye C, Wang J, Zheng S, Chai Y. Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis. Onco Targets Ther 2016;9:6605-8. [PMID: 27822065 DOI: 10.2147/OTT.S121923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
199 Zhao Z, Verma V, Zhang M. Anaplastic lymphoma kinase: Role in cancer and therapy perspective. Cancer Biol Ther. 2015;16:1691-1701. [PMID: 26529396 DOI: 10.1080/15384047.2015.1095407] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
200 Mansfield AS, Murphy SJ, Harris FR, Robinson SI, Marks RS, Johnson SH, Smadbeck JB, Halling GC, Yi ES, Wigle D, Vasmatzis G, Jen J. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Ann Oncol 2016;27:2111-7. [PMID: 27742657 DOI: 10.1093/annonc/mdw405] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
201 Toyokawa G, Seto T, Takenoyama M, Ichinose Y. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev 2015;34:797-805. [PMID: 26342831 DOI: 10.1007/s10555-015-9592-y] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
202 Brcic L, Jakopovic M, Misic M, Seiwerth F, Kern I, Smojver-Jezek S, Quehenberger F, Samarzija M, Seiwerth S. Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. Diagn Pathol 2016;11:90. [PMID: 27655296 DOI: 10.1186/s13000-016-0544-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
203 Gao X, Sholl LM, Nishino M, Heng JC, Jänne PA, Oxnard GR. Clinical Implications of Variant ALK FISH Rearrangement Patterns. J Thorac Oncol 2015;10:1648-52. [PMID: 26536196 DOI: 10.1097/JTO.0000000000000665] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
204 Noronha V, Ramaswamy A, Patil VM, Joshi A, Chougule A, Kane S, Kumar R, Sahu A, Doshi V, Nayak L, Mahajan A, Janu A, Prabhash K. ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. PLoS One 2016;11:e0160752. [PMID: 27637025 DOI: 10.1371/journal.pone.0160752] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
205 Baldacci S, Cortot A. Les cancers bronchiques non à petites cellules EGFR-mutés. Revue des Maladies Respiratoires Actualités 2016;8:373-381. [DOI: 10.1016/s1877-1203(16)30126-4] [Reference Citation Analysis]
206 Qian L, Lin L, Du Y, Hao X, Zhao Y, Liu X. MicroRNA-588 suppresses tumor cell migration and invasion by targeting GRN in lung squamous cell carcinoma. Mol Med Rep 2016;14:3021-8. [PMID: 27571908 DOI: 10.3892/mmr.2016.5643] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
207 Gu FF, Zhang Y, Liu YY, Hong XH, Liang JY, Tong F, Yang JS, Liu L. Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy. J Hematol Oncol 2016;9:66. [PMID: 27496196 DOI: 10.1186/s13045-016-0296-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
208 Karlsson A, Brunnström H, Lindquist KE, Jirström K, Jönsson M, Rosengren F, Reuterswärd C, Cirenajwis H, Borg Å, Jönsson P, Planck M, Jönsson G, Staaf J. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget 2015;6:22028-37. [PMID: 26124082 DOI: 10.18632/oncotarget.4314] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
209 Facchinetti F, Tiseo M, Di Maio M, Graziano P, Bria E, Rossi G, Novello S. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res 2016;5:301-21. [PMID: 27413712 DOI: 10.21037/tlcr.2016.06.10] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
210 Gillis NK, McLeod HL. The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat 2016;28:28-42. [PMID: 27620953 DOI: 10.1016/j.drup.2016.06.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
211 Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience 2016;10:648. [PMID: 27433281 DOI: 10.3332/ecancer.2016.648] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
212 Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J 2015;21:378-82. [PMID: 26389762 DOI: 10.1097/PPO.0000000000000142] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
213 Saleh T, Cuttino L, Gewirtz DA. Autophagy is not uniformly cytoprotective: a personalized medicine approach for autophagy inhibition as a therapeutic strategy in non-small cell lung cancer. Biochim Biophys Acta 2016;1860:2130-6. [PMID: 27316314 DOI: 10.1016/j.bbagen.2016.06.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
214 Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn 2016;16:737-49. [PMID: 27139190 DOI: 10.1080/14737159.2016.1181545] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
215 Shiroyama T, Tamiya M, Hayama M, Nishihara T, Nishida T, Tanaka A, Morishita N, Suzuki H, Okamoto N, Kawahara K, Hirashima T. A heterochronic genetic change from an EGFR mutation to an ALK rearrangement in a patient with lung adenocarcinoma: a case report. J Thorac Dis 2016;8:E345-8. [PMID: 27162697 DOI: 10.21037/jtd.2016.03.43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
216 Ma D, Hao X, Wang Y, Xing P, Li J. Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Thorac Cancer 2016;7:452-8. [PMID: 27385988 DOI: 10.1111/1759-7714.12353] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
217 Rothschild SI. New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib. Ther Clin Risk Manag 2016;12:735-41. [PMID: 27217763 DOI: 10.2147/TCRM.S87876] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
218 Lee T, Lee B, Choi YL, Han J, Ahn MJ, Um SW. Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. J Pathol Transl Med 2016;50:197-203. [PMID: 27086595 DOI: 10.4132/jptm.2016.03.09] [Cited by in Crossref: 49] [Cited by in F6Publishing: 64] [Article Influence: 7.0] [Reference Citation Analysis]
219 Wen M, Wang X, Sun Y, Xia J, Fan L, Xing H, Zhang Z, Li X. Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. Onco Targets Ther. 2016;9:1989-1995. [PMID: 27103824 DOI: 10.2147/ott.s100303] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
220 Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol 2015;10:768-77. [PMID: 25738220 DOI: 10.1097/JTO.0000000000000516] [Cited by in Crossref: 239] [Cited by in F6Publishing: 266] [Article Influence: 34.1] [Reference Citation Analysis]
221 Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015;21:2227-35. [PMID: 25979929 DOI: 10.1158/1078-0432.CCR-14-2791] [Cited by in Crossref: 168] [Cited by in F6Publishing: 193] [Article Influence: 24.0] [Reference Citation Analysis]
222 Dong YJ, Cai YR, Zhou LJ, Su D, Mu J, Chen XJ, Zhang LI. Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification. Oncol Lett 2016;11:2552-8. [PMID: 27073516 DOI: 10.3892/ol.2016.4233] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
223 Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci 2016;73:1209-24. [PMID: 26755435 DOI: 10.1007/s00018-015-2117-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 9.0] [Reference Citation Analysis]
224 Suenaga M, Lenz H, Scherer SJ. Overview of Oncology Biomarkers. Pharmacokinetics in Drug Development 2016. [DOI: 10.1007/978-3-319-39053-6_2] [Reference Citation Analysis]
225 Kurashige R, Sakashita H, Higashi S, Uchibori K, Kihara A, Inase N. A Case of ALK-rearrangement-positive Lung Adenocarcinoma Successfully Treated with Crizotinib for Rapid Progression After the Discontinuation of Alectinib. JJLC 2016;56:308-313. [DOI: 10.2482/haigan.56.308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
226 Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine 2016;3:54-66. [PMID: 26870817 DOI: 10.1016/j.ebiom.2015.12.009] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 11.3] [Reference Citation Analysis]
227 Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S, Liu D, Ye X, Ye M, Yang J, Shao L, Pan H, Lu N, Yu Y, Liu L, Li J, Huang L, Tang H, Deng Q, Zheng Y, Peng L, Liu G, Gu X, He P, Gu Y, Lin W, He H, Xie G, Liang H, An N, Wang H, Teixeira M, Vieira J, Liang W, Zhao X, Peng Z, Mu F, Zhang X, Xu X, Yang H, Kristiansen K, Wang J, Zhong N, Wang J, Pan-Hammarström Q, He J. Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun 2015;6:10131. [PMID: 26647728 DOI: 10.1038/ncomms10131] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 8.1] [Reference Citation Analysis]
228 Zheng D, Wang R, Zhang Y, Pan Y, Cheng X, Cheng C, Zheng S, Li H, Gong R, Li Y, Shen X, Sun Y, Chen H. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations. J Cancer Res Clin Oncol 2016;142:833-43. [PMID: 26646246 DOI: 10.1007/s00432-015-2081-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
229 Hatcher JM, Bahcall M, Choi HG, Gao Y, Sim T, George R, Jänne PA, Gray NS. Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. J Med Chem 2015;58:9296-308. [PMID: 26568289 DOI: 10.1021/acs.jmedchem.5b01136] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
230 Gower A, Hsu WH, Hsu ST, Wang Y, Giaccone G. EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer. Mol Oncol 2016;10:601-9. [PMID: 26639656 DOI: 10.1016/j.molonc.2015.11.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
231 Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Harada M, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol 2016;27:185-92. [PMID: 26487585 DOI: 10.1093/annonc/mdv501] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
232 Guo L, Zhang H, Shao W, Chen B. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. Drug Des Devel Ther 2015;9:5491-7. [PMID: 26491259 DOI: 10.2147/DDDT.S91988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
233 Roviello G. The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther 2015;8:2399-406. [PMID: 26366094 DOI: 10.2147/OTT.S89225] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
234 Liao BC, Lin CC, Shih JY, Yang JC. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol 2015;7:274-90. [PMID: 26327925 DOI: 10.1177/1758834015590593] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
235 Li S, Zhao L, Zhang J, Zou Z, Du P. Inhibition of lung adenocarcinoma cells by insulin-like growth factor-I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide. Thorac Cancer 2015;6:260-8. [PMID: 26273371 DOI: 10.1111/1759-7714.12176] [Reference Citation Analysis]
236 Fang B, Mehran RJ, Heymach JV, Swisher SG. Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer 2015;34:295-309. [PMID: 26134262 DOI: 10.1186/s40880-015-0028-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
237 Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press) 2015;7:111-23. [PMID: 26028978 DOI: 10.2147/BCTT.S60696] [Cited by in Crossref: 45] [Cited by in F6Publishing: 80] [Article Influence: 5.6] [Reference Citation Analysis]
238 Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L, Zhang L, Wang C, Zhang H, Wei L. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. Tumour Biol 2015;36:6417-24. [PMID: 25813151 DOI: 10.1007/s13277-015-3331-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
239 Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Ann Oncol 2015;26:894-901. [PMID: 25722381 DOI: 10.1093/annonc/mdv072] [Cited by in Crossref: 215] [Cited by in F6Publishing: 231] [Article Influence: 26.9] [Reference Citation Analysis]
240 Jiang T, Zhou C. [Treatment of patients with ALK gene rearranged non-small cell lung cancer 
after resistance to crizotinib]. Zhongguo Fei Ai Za Zhi 2015;18:69-74. [PMID: 25676398 DOI: 10.3779/j.issn.1009-3419.2015.02.03] [Reference Citation Analysis]
241 Liu Q, Wang M, Kern AM, Khaled S, Han J, Yeap BY, Hong TS, Settleman J, Benes CH, Held KD, Efstathiou JA, Willers H. Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res 2015;13:713-20. [PMID: 25667133 DOI: 10.1158/1541-7786.MCR-14-0570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
242 Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014;5:1392-433. [PMID: 24722523 DOI: 10.18632/oncotarget.1891] [Cited by in Crossref: 127] [Cited by in F6Publishing: 142] [Article Influence: 15.9] [Reference Citation Analysis]
243 Markou A, Sourvinou I, Balkouranidou I, Lianidou ES. Epigenetics and Biomarkers in Lung Cancer: Emerging Blood-Based Molecular Biomarkers for Detection and Monitoring. Biomarkers in Cancer 2015. [DOI: 10.1007/978-94-007-7681-4_35] [Reference Citation Analysis]
244 Moreira AL. Role of Immunohistochemistry in the Detection of Targetable Mutations. Diagnosing Non-small Cell Carcinoma in Small Biopsy and Cytology 2015. [DOI: 10.1007/978-1-4939-1607-8_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
245 Ma L, Zhang S. [Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2014;17:850-4. [PMID: 25539610 DOI: 10.3779/j.issn.1009-3419.2014.12.05] [Reference Citation Analysis]
246 Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014;6:423-32. [PMID: 25429239 DOI: 10.2147/CLEP.S69718] [Cited by in Crossref: 97] [Cited by in F6Publishing: 107] [Article Influence: 10.8] [Reference Citation Analysis]
247 Sun Q, Wu JY, Jiao SC. Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report. Oncol Lett 2014;8:2093-5. [PMID: 25295096 DOI: 10.3892/ol.2014.2468] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
248 Migali C, Bielinska AM, Bhosle J, O'brien M. Development in the diagnostic lung cancer pathway: implication for treatment. Lung Cancer Management 2014;3:417-28. [DOI: 10.2217/lmt.14.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, Paz-Ares L, Hardisson D, de Castro J, Camacho MC, Rodriguez-Abreu D, Abdulkader I, Ramirez J, Reguart N, Salido M, Pijuán L, Arriola E, Sanz J, Folgueras V, Villanueva N, Gómez-Román J, Hidalgo M, López-Ríos F. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One 2014;9:e107200. [PMID: 25248157 DOI: 10.1371/journal.pone.0107200] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
250 Fortunato O, Boeri M, Verri C, Moro M, Sozzi G. Therapeutic use of microRNAs in lung cancer. Biomed Res Int 2014;2014:756975. [PMID: 25309923 DOI: 10.1155/2014/756975] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
251 Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014;20:1027-34. [PMID: 25173427 DOI: 10.1038/nm.3667] [Cited by in Crossref: 193] [Cited by in F6Publishing: 206] [Article Influence: 21.4] [Reference Citation Analysis]
252 Spaans JN, Goss GD. Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. Front Oncol 2014;4:233. [PMID: 25221748 DOI: 10.3389/fonc.2014.00233] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
253 Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2014;74:437-46. [PMID: 25135623 DOI: 10.1007/s00280-014-2517-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
254 Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013;73:2031-51. [PMID: 24288180 DOI: 10.1007/s40265-013-0142-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
255 Cha YJ, Lee JS, Kim HR, Lim SM, Cho BC, Lee CY, Shim HS. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One 2014;9:e103333. [PMID: 25058391 DOI: 10.1371/journal.pone.0103333] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 6.8] [Reference Citation Analysis]
256 Palma NA, Ali SM, O'Connor J, Dutta D, Wang K, Soman S, Palmer GA, Morosini D, Ross JS, Lipson D, Stephens PJ, Patel M, Miller VA, Koutrelakos N. Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. Case Rep Oncol 2014;7:503-8. [PMID: 25232318 DOI: 10.1159/000365326] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
257 Spaans JN, Goss GD. Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. Front Oncol 2014;4:190. [PMID: 25101246 DOI: 10.3389/fonc.2014.00190] [Cited by in Crossref: 29] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
258 Esfahani K, Agulnik JS, Cohen V. A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2014;4:174. [PMID: 25101240 DOI: 10.3389/fonc.2014.00174] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
259 Pender A, Popat S. Understanding lung cancer molecular subtypes. Clinical Practice 2014;11:441-53. [DOI: 10.2217/cpr.14.39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
260 Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013;5 Suppl 5:S579-92. [PMID: 24163750 DOI: 10.3978/j.issn.2072-1439.2013.08.52] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
261 Fan L, Feng Y, Wan H, Shi G, Niu W. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. PLoS One 2014;9:e100866. [PMID: 24959902 DOI: 10.1371/journal.pone.0100866] [Cited by in Crossref: 25] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
262 Fujimoto J, Wistuba II. Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol 2014;31:306-13. [PMID: 25239274 DOI: 10.1053/j.semdp.2014.06.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
263 Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 2014;8:1495-507. [PMID: 24962792 DOI: 10.1016/j.molonc.2014.06.001] [Cited by in Crossref: 102] [Cited by in F6Publishing: 112] [Article Influence: 11.3] [Reference Citation Analysis]
264 Gower A, Wang Y, Giaccone G. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl) 2014;92:697-707. [PMID: 24852181 DOI: 10.1007/s00109-014-1165-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
265 Abel HJ, Al-Kateb H, Cottrell CE, Bredemeyer AJ, Pritchard CC, Grossmann AH, Wallander ML, Pfeifer JD, Lockwood CM, Duncavage EJ. Detection of gene rearrangements in targeted clinical next-generation sequencing. J Mol Diagn 2014;16:405-17. [PMID: 24813172 DOI: 10.1016/j.jmoldx.2014.03.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
266 Zhu X, Li H, Cao B, Liu C, Liang L, Wang Y, You J, Gao F, Ma X, Liu Y, Wang H, Zhang Y, Chen J, Zhang B. [The research of clinical pathological features of ALK positive lung cancer in 525 patients and the discussion of detection methods]. Zhongguo Fei Ai Za Zhi 2014;17:226-32. [PMID: 24667260 DOI: 10.3779/j.issn.1009-3419.2014.03.08] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
267 Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4:662-673. [PMID: 24675041 DOI: 10.1158/2159-8290.cd-13-0846] [Cited by in Crossref: 555] [Cited by in F6Publishing: 624] [Article Influence: 61.7] [Reference Citation Analysis]
268 Wang M, Kern AM, Hülskötter M, Greninger P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, Efstathiou JA, Settleman J, Willers H. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res 2014;74:2825-34. [PMID: 24648348 DOI: 10.1158/0008-5472.CAN-13-3157] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
269 Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M. Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev 2014;28:561-75. [PMID: 24589553 DOI: 10.1101/gad.233627.113] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 6.9] [Reference Citation Analysis]
270 Hu L, Ru K, Zhang L, Huang Y, Zhu X, Liu H, Zetterberg A, Cheng T, Miao W. Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine.Biomark Res. 2014;2:3. [PMID: 24499728 DOI: 10.1186/2050-7771-2-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
271 Wang J, Dong Y, Cai Y, Zhou L, Wu S, Liu G, Su D, Li X, Qin N, Nong J, Jia H, Zhang Q, Mu J, Zeng X, Zhang H, Zhang S, Zhang Z. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status. J Cancer Res Clin Oncol 2014;140:453-60. [PMID: 24442099 DOI: 10.1007/s00432-014-1584-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
272 Markou A, Sourvinou I, Balkouranidou I, Lianidou ES. Epigenetics and Biomarkers in Lung Cancer: Emerging Blood-Based Molecular Biomarkers for Detection and Monitoring. Biomarkers in Cancer 2014. [DOI: 10.1007/978-94-007-7744-6_35-1] [Reference Citation Analysis]
273 Kim MH, Park Y, Park HJ, Ji A, Song C, Jin M, Kim YJ, Kim SW, Lee J, Kim I, Kim HR, Kim J, Cho BC. A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant ActivatingEGFRMutation andROS1Rearrangement. Ewha Med J 2014;37:46. [DOI: 10.12771/emj.2014.37.1.46] [Reference Citation Analysis]
274 Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest 2014;94:129-37. [PMID: 24378644 DOI: 10.1038/labinvest.2013.147] [Cited by in Crossref: 141] [Cited by in F6Publishing: 156] [Article Influence: 14.1] [Reference Citation Analysis]
275 Rossing HH, Grauslund M, Urbanska EM, Melchior LC, Rask CK, Costa JC, Skov BG, Sørensen JB, Santoni-Rugiu E. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Res Notes 2013;6:489. [PMID: 24279718 DOI: 10.1186/1756-0500-6-489] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
276 Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013;13:772-787. [PMID: 24132104 DOI: 10.1038/nrc3612] [Cited by in Crossref: 220] [Cited by in F6Publishing: 230] [Article Influence: 22.0] [Reference Citation Analysis]